SCHEMBL982528

SCHEMBL982528

O=C(Cc1ccc2[nH]cnc2c1)N1CCC(c2ccc(Cl)cc2)=N1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 8/20 0.41
ALDH1A1 P00352 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39
LMNA P02545 2/20 0.39
POLB P06746 1/20 0.39
PKM P14618 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MAPT P10636 2/20 0.39
GAA P10253 1/20 0.38
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
MET P08581 1/20 0.36
TP53 P04637 1/20 0.35
TYMS P04818 1/20 0.35
ECE2 P0DPD6 1/20 0.34
QPCT Q16769 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL981997 0.89 ALDH1A1 (0.38) PGRALDH1A1SMN1; SMN2HPGDRAB9A
SCHEMBL17004375 0.89 ORAI1 (0.39) PGRALDH1A1SMN1; SMN2HPGDRAB9A
SCHEMBL981799 0.87 MET (0.48) SMN1; SMN2L3MBTL1LMNAPOLBMET
SCHEMBL979465 0.86 MET (0.41) ALDH1A1SMN1; SMN2L3MBTL1HPGDLMNA
SCHEMBL980139 0.86 SMN1; SMN2 (0.35) ALDH1A1SMN1; SMN2HPGDRAB9APOLB
SCHEMBL4628246 0.83 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2HPGDRAB9APOLB
SCHEMBL979214 0.83 GRM5 (0.38) PGRALDH1A1SMN1; SMN2HPGDRAB9A
SCHEMBL981952 0.81 PARP1 (0.34) METTYMSECE2
SCHEMBL980254 0.80 PGR (0.46) PGRALDH1A1SMN1; SMN2L3MBTL1HPGD
SCHEMBL982007 0.78 ME2 (0.51) PGRALDH1A1SMN1; SMN2L3MBTL1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP claimed
US-7875644-B2 tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas MERCK PATENT GMBH (DE) 2011-01-25 US claimed
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MERCK PATENT GESELLSCHAFT (DE) 2008-10-09 US claimed
EP-1917248-A1 1-ACYLDIHYDROPYRAZOL DERIVATIVES Merck Patent GmbH (DE) 2008-05-07 EP claimed
WO-2007019933-A1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2007-02-22 WO claimed
EP-1917248-B1 1-ACYLDIHYDROPYRAZOL DERIVATIVES MERCK PATENT GMBH (DE) 2015-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249095-A1 1-Acyldihydropyrazole Derivatives MET, FLT3, ERBB3 PGR 1338/4885ALDH1A1 399/4885SMN1; SMN2 4245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.